Liquid Biopsy Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Liquid Biopsy Market Size By 2025?
Expansion within the realm of liquid biopsy has been quite swift over recent years, projecting an increase from a valuation of $1.25 billion in 2024 up to $1.46 billion just one year later in 2025, charting a notable compound annual growth rate (CAGR) of 16.1%; this upward trajectory during the observed period fundamentally owes its momentum to progress in oncology studies, the inherent characteristic of being non-invasive, the rise of customized medical treatments, the acquisition of necessary regulatory clearances, and enhanced capabilities in identifying malignancies at an earlier stage.

How Big Is the Liquid Biopsy Market Size Expected to Grow by 2029?
Anticipation points toward brisk expansion within the liquid biopsy sector over the ensuing years, projecting a market valuation skyrocketing to $2.7 billion by 2029, propelled by a compound annual growth rate (CAGR) of 16.7%; this upward trajectory during the projection timeframe is largely fueled by the wider adoption across various applications, advancements in cancer surveillance, the proliferation of nascent technologies, the rise of companion diagnostics, and ongoing biomarker identification efforts, while key prevailing patterns shaping this period involve intensified focus on cancer screening and ongoing assessment, therapeutic progress tracking, monitoring of minimal residual disease (mrd), and the penetration of liquid biopsy techniques into arenas beyond oncology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Key Market Drivers Powering Liquid Biopsy Market Expansion and Growth?
The expansion of the liquid biopsy market is principally fueled by governmental financial support dedicated to enhancing cancer detection methodologies. Such capital injections from governments assist scientific investigators in their pursuits across the spectrum of disease management, specifically in finding new drugs, improving diagnostic tools, and developing therapeutic strategies for ailments like malignant tumors. To illustrate this support, the US medical research body, the National Institute of Health (NIH), received an allocation of $46.6 billion in 2022, with the American cancer research organization, the National Cancer Institute (NCI), specifically being awarded $6.9 billion to push forward cancer investigations; consequently, public sector financing exerts a beneficial influence upon the upward trajectory of the liquid biopsy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Liquid Biopsy Market?
To align with evolving market conditions and boost profitability while outmaneuvering competitors, organizations are increasingly prioritizing the introduction of sophisticated products and services pertaining to liquid biopsies to satisfy the surging demand. A prime illustration of this trend is the introduction in June 2023 by Laboratory Corporation of America Holdings, a healthcare entity situated in the United States, of a liquid biopsy diagnostic named Labcorp Plasma Focus. This particular assay is engineered for the detection of cancer-related biomarkers in patients diagnosed with metastatic or advanced solid tumors. The process involves analyzing the circulating cell-free DNA (cfDNA) present in a blood sample from the patient to establish a comprehensive genomic map of their malignancy. Consequently, physicians specializing in oncology are equipped to refine patient treatment protocols through the formulation of individualized and highly specific therapeutic plans, underscoring significant corporate investment in cutting-edge liquid biopsy innovations.

What Are the Emerging Segments in the Liquid Biopsy Market?
The liquid biopsymarket covered in this report is segmented -

1) By Product: Assays Kits; Instruments; Services
2) By Clinical Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring Orthopedics
3) By End User: Reference Laboratories; Hospitals and Physician Laboratories; Academic and Research Centers

Subsegments:
1) By Assays Kits: cfDNA Assays; ctDNA Assays; Exosome-based Assays; RNA-based Assays; Protein-based Assays
2) By Instruments: PCR Instruments; Next-Generation Sequencing (NGS) Instruments; Microarray Instruments; Mass Spectrometry Instruments
3) By Services: Testing Services; Data Analysis Services; Laboratory Services; Custom Assay Development Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Who Are the Global Leaders in the Liquid Biopsy Market?
Major companies operating in the liquid biopsy market include QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Which are the Top Profitable Regional Markets for the Liquid Biopsy Industry?
North America was the largest region in the liquid biopsy market in 2024. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2815

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.